
It was a violation of European competition law when Lundbeck made deals with four generics manufacturers concerning its antidepressant citalopram, the European Commission has decided according to a press release from the Danish company, which also reveals Lundbeck’s intentions to appeal the decision.
“We are surprised and disappointed that the EU commission has reached this erroneous conclusion, which we totally disagree with, and it is therefore our intention to appeal,” says Ulf Wiinberg, CEO of Lundbeck.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app